{"organizations": [], "uuid": "b1280bd1a087b3d4f0662a619b0e870cc709f2dc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-enanta-pharmaceuticals-says-phase/brief-enanta-pharmaceuticals-says-phase-1-clinical-study-of-edp-938-for-respiratory-syncytial-virus-initiated-idUSASB0BZVS", "country": "US", "domain_rank": 408, "title": "BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T14:33:00.000+02:00", "replies_count": 0, "uuid": "b1280bd1a087b3d4f0662a619b0e870cc709f2dc"}, "author": "", "url": "https://www.reuters.com/article/brief-enanta-pharmaceuticals-says-phase/brief-enanta-pharmaceuticals-says-phase-1-clinical-study-of-edp-938-for-respiratory-syncytial-virus-initiated-idUSASB0BZVS", "ord_in_thread": 0, "title": "BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated", "locations": [], "entities": {"persons": [{"name": "respir", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "brief-enanta pharmaceuticals says phase", "sentiment": "negative"}, {"name": "j.p. morgan healthcare", "sentiment": "none"}, {"name": "enanta pharmaceuticals", "sentiment": "none"}, {"name": "syncytial virus initiated reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "enanta pharmaceuticals inc", "sentiment": "none"}, {"name": "enanta pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 33 PM / in 9 minutes BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated Reuters Staff 1 Min Read \nJan 5 (Reuters) - Enanta Pharmaceuticals Inc: \n* ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE \n* ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF EDP-938 FOR RESPIRATORY SYNCYTIAL VIRUS INITIATED \n* ENANTA PHARMACEUTICALS INC - PHASE 2 CLINICAL STUDY “INTREPID” OF EDP-305 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INITIATED \n* ENANTA PHARMACEUTICALS INC - STRONG CASH BALANCE OF $294M AS OF SEPTEMBER 30, 2017 TO SUPPORT ADVANCING RESEARCH AND DEVELOPMENT PROGRAMS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T14:33:00.000+02:00", "crawled": "2018-01-05T14:48:57.011+02:00", "highlightTitle": ""}